ADIA Adia Med, Inc.
Medicinal Chemicals & Botanical Products · OTC · SEC CIK 1160420 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin35.3%
Operating margin-38.0%
Net margin-41.5%
FCF margin-27.2%
EBITDA margin-37.5%
Returns
ROE-111.0%
ROA—
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets60.4%
Debt / equity0.00x
Current ratio1.09x
Interest coverage-20.10x
Cash quality & payout
Operating cash flow / net income0.62x
Accruals ratio—
Payout ratio—
Capex / revenue1.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $700,508 | $6,380 |
| Cost of revenue | $508,838 | $4,186 |
| Gross profit | $191,670 | $2,194 |
| R&D expense | $29,144 | $0 |
| SG&A expense | $479,955 | $140,409 |
| Operating income | -$366,492 | -$174,749 |
| Interest expense | $31,597 | $6,318 |
| Pretax income | -$395,464 | -$181,067 |
| Income tax | $0 | $0 |
| Net income | -$395,464 | -$181,067 |
| EBITDA | -$362,350 | -$174,316 |
| EPS (basic) | 0.00 | 0.00 |
| EPS (diluted) | 0.00 | 0.00 |
| Weighted avg. shares (diluted) | 93.60M | 91.74M |
| Balance sheet | ||
| Cash & equivalents | $79,392 | $6,323 |
| Receivables | $33,360 | $0 |
| Inventory | $25,025 | $206,886 |
| Current assets | $161,510 | $258,393 |
| PP&E, net | $30,695 | $21,637 |
| Intangibles | $0 | $5,910 |
| Total assets | $594,826 | $666,181 |
| Current liabilities | $745,195 | $79,993 |
| Total liabilities | $852,500 | $640,641 |
| Shareholders' equity | -$257,674 | $25,540 |
| Cash flow statement | ||
| Operating cash flow | -$179,228 | -$335,476 |
| Capital expenditure | $13,200 | $21,831 |
| Free cash flow | -$192,428 | -$357,307 |
| Investing cash flow | -$32,051 | -$25,980 |
| Financing cash flow | $284,348 | $367,279 |
| Depreciation & amortization | $4,142 | $433 |
| Stock-based compensation | $42,250 | $30,857 |
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.